Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 2, 2024
Daily News
August 2, 2024
- Kyowa Kirin Pulls Plug on Stand-Alone Sales in China, Retools Asian Strategy
August 2, 2024
- Otsuka Picks Up Jnana Therapeutics for US$800 Million
August 2, 2024
- Off-Year Debate Would Explore Ways to Address Drug Loss, Supply Issues with Drug Prices: Vice Minister
August 2, 2024
- Kyowa Kirin to Offer Buyout Packages amid Research Rejig
August 2, 2024
- Otsuka’s H1 Pharma Sales Soar 18% on Rexulti, Lonsurf
August 2, 2024
- Ono Inks Fresh GPCR Antibody Pact with Monash University
August 2, 2024
- Mitsubishi Tanabe’s Buyout Program Has No Bearing on Potential Divestment: EVP
August 2, 2024
- Lilly’s Alzheimer’s Med Donanemab Now in Line for Japan Approval
August 2, 2024
- Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
August 2, 2024
- Leqembi’s April-June Sales Up 2.2-Fold from Prior Quarter: Eisai
August 2, 2024
- Maruho, Meiji to End Co-Promotion of Amenalief in Japan
August 2, 2024
- The Dynamics of Field Medical Visits: Importance of Balancing Quality and Frequency in Medical Interactions
August 2, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…